Cancer Family
Thymus Neoplasm
CI-CAN-00000366Explore in graph →
Non-malignant104 active trials1 approved drugs1 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000366Explore in graph →
Clinical trials
283 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04358458 | First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas | terminated | Phase 1 / Phase 2 | 46 | GenmabINDUSTRY | 5 | Oct 24, 2024 | clinicaltrials |
| NCT04925947 | A Study of KN046 in Patients With Thymic Carcinoma Who Failed Immune Checkpoint Inhibitors | terminated | Phase 2 | 4 | Weill Medical College of Cornell UniversityOTHER | 1 | Apr 16, 2024 | clinicaltrials |
| NCT04469725 | KN046 (a Humanized PD-L1/CTLA4 Bispecific Single Domain Fc Fusion Protein Antibody) in Subjects With Thymic Carcinoma | terminated | Phase 2 | 95 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | Mar 12, 2024 | clinicaltrials |
| NCT03193437 | Selinexor in Patients With Advanced Thymic Epithelial Tumor Progressing After Primary Chemotherapy(SELECT) | terminated | Phase 2 | 8 | Georgetown UniversityOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT02859415 | Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases | terminated | Phase 1 / Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | Apr 5, 2022 | clinicaltrials |
| NCT02062632 | Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy | terminated | Phase 2 | 5 | Mayo ClinicOTHER | 1 | Oct 1, 2019 | clinicaltrials |
| NCT01011439 | Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma | terminated | Phase 2 | 72 | Tiziana Life Sciences LTDINDUSTRY | 3 | Feb 6, 2019 | clinicaltrials |
| NCT01301391 | Study Of Oral PHA-848125AC In Patients With Malignant Thymoma Previously Treated With Multiple Lines Of Chemotherapy | terminated | Phase 2 | 30 | Tiziana Life Sciences LTDINDUSTRY | 2 | Feb 6, 2019 | clinicaltrials |
| NCT01100944 | A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, Malignancies | terminated | Phase 1 / Phase 2 | 26 | National Cancer Institute (NCI)NIH | 1 | Aug 10, 2017 | clinicaltrials |
| NCT00718809 | Saracatinib in Treating Patients With Relapsed or Refractory Thymoma or Thymic Cancer | terminated | Phase 2 | 21 | National Cancer Institute (NCI)NIH | 1 | Jun 10, 2015 | clinicaltrials |
| NCT00818090 | Paclitaxel and Cisplatin for Thymic Neoplasm | terminated | Phase 2 | 39 | Korean Cancer Study GroupOTHER | 1 | Apr 12, 2013 | clinicaltrials |
Data updated 22 days agoSource updated Oct 24, 2024source: clinicaltrials